Compare NEON & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | INTS |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 13.7M |
| IPO Year | 1994 | 2021 |
| Metric | NEON | INTS |
|---|---|---|
| Price | $0.89 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | ★ 46.6K | 14.1K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $28.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.22 |
| 52 Week High | $3.81 | $8.06 |
| Indicator | NEON | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 43.17 |
| Support Level | $0.83 | $0.30 |
| Resistance Level | $0.95 | $4.30 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 61.40 | 34.86 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.